Anorexia Nervosa (AN)

Also known as: Anorexia Nervosa / Nervosas, Anorexia

DrugDrug NameDrug Description
DB00321AmitriptylineAmitriptyline hydrochloride, also known as _Elavil_, is a tricyclic antidepressant (TCA) with analgesic properties, widely used to treat depression and neuropathic pain [A174658]. It was originally approved by the FDA in 1977 and manufactured by Sandoz [L5308].
DB00215CitalopramCitalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
DB00434CyproheptadineA serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
DB01151DesipramineDesipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
DB00472FluoxetineFluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.
DB00370MirtazapineMirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994.[A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.[A177811]
DrugDrug NameTargetType
DB00321AmitriptylineSodium-dependent serotonin transportertarget
DB00321AmitriptylineSodium-dependent noradrenaline transportertarget
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 2target
DB00321AmitriptylineAlpha-2A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 1A2enzyme
DB00321AmitriptylineCytochrome P450 2C19enzyme
DB00321AmitriptylineCytochrome P450 2D6enzyme
DB00321AmitriptylineSerum albumincarrier
DB00321AmitriptylineAlpha-1-acid glycoprotein 1carrier
DB00321AmitriptylineHistamine H1 receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 2Atarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Atarget
DB00321AmitriptylineAlpha-1A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 3A4enzyme
DB00321AmitriptylineCytochrome P450 3A5enzyme
DB00321AmitriptylinePotassium voltage-gated channel subfamily A member 1target
DB00321AmitriptylineAlpha-1D adrenergic receptortarget
DB00321AmitriptylineDelta-type opioid receptortarget
DB00321AmitriptylineKappa-type opioid receptortarget
DB00321AmitriptylineHigh affinity nerve growth factor receptortarget
DB00321AmitriptylineBDNF/NT-3 growth factors receptortarget
DB00321AmitriptylineCytochrome P450 2C9enzyme
DB00321AmitriptylineCytochrome P450 2B6enzyme
DB00321AmitriptylineCytochrome P450 2C8enzyme
DB00321AmitriptylineHistamine H2 receptortarget
DB00321AmitriptylineHistamine H4 receptortarget
DB00321AmitriptylineSigma non-opioid intracellular receptor 1target
DB00321Amitriptyline5-hydroxytryptamine receptor 2Ctarget
DB00321AmitriptylineAlpha-1B adrenergic receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 7target
DB00321Amitriptyline5-hydroxytryptamine receptor 1Dtarget
DB00321AmitriptylineMu-type opioid receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Btarget
DB00321Amitriptyline5-hydroxytryptamine receptor 6target
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 3target
DB00321AmitriptylineUDP-glucuronosyltransferase 1-1enzyme
DB00321Amitriptyline5-hydroxytryptamine receptor 1Ctarget
DB00321AmitriptylineMuscarinic acetylcholine receptortarget
DB00321AmitriptylineHERG human cardiac K+ channeltarget
DB00321AmitriptylineMultidrug resistance protein 1transporter
DB00215CitalopramSodium-dependent serotonin transportertarget
DB00215CitalopramCytochrome P450 2C19enzyme
DB00215CitalopramCytochrome P450 2D6enzyme
DB00215CitalopramCytochrome P450 3A4enzyme
DB00215CitalopramMultidrug resistance protein 1transporter
DB00215CitalopramCytochrome P450 1A2enzyme
DB00215CitalopramHistamine H1 receptortarget
DB00434Cyproheptadine5-hydroxytryptamine receptor 2Atarget
DB00434CyproheptadineHistamine H1 receptortarget
DB00434CyproheptadineMuscarinic acetylcholine receptor M1target
DB00434CyproheptadineMuscarinic acetylcholine receptor M2target
DB00434CyproheptadineMuscarinic acetylcholine receptor M3target
DB00434Cyproheptadine5-hydroxytryptamine receptor 2Ctarget
DB00434CyproheptadineUDP-glucuronosyltransferase 1-3enzyme
DB00434Cyproheptadine5-hydroxytryptamine receptor 7target
DB01151DesipramineMuscarinic acetylcholine receptor M1target
DB01151DesipramineSodium-dependent noradrenaline transportertarget
DB01151DesipramineBeta-2 adrenergic receptortarget
DB01151DesipramineMuscarinic acetylcholine receptor M2target
DB01151DesipramineSodium-dependent serotonin transportertarget
DB01151DesipramineHistamine H1 receptortarget
DB01151DesipramineBeta-1 adrenergic receptortarget
DB01151DesipramineCytochrome P450 2D6enzyme
DB01151DesipramineMuscarinic acetylcholine receptor M3target
DB01151DesipramineMuscarinic acetylcholine receptor M4target
DB01151DesipramineMuscarinic acetylcholine receptor M5target
DB01151DesipramineAlpha-1 adrenergic receptorstarget
DB01151Desipramine5-hydroxytryptamine receptor 2Atarget
DB01151DesipramineAlpha-1-acid glycoprotein 1carrier
DB01151DesipramineCytochrome P450 2B6enzyme
DB01151DesipramineCytochrome P450 3A4enzyme
DB01151DesipramineSolute carrier family 22 member 2transporter
DB01151DesipramineSolute carrier family 22 member 1transporter
DB01151DesipramineSolute carrier family 22 member 3transporter
DB01151DesipramineSolute carrier family 22 member 5transporter
DB01151DesipramineMultidrug resistance protein 1transporter
DB01151DesipramineSolute carrier family 22 member 4transporter
DB01151DesipramineCytochrome P450 1A2enzyme
DB01151DesipramineCytochrome P450 2A6enzyme
DB01151DesipramineCytochrome P450 2C18enzyme
DB01151DesipramineCytochrome P450 2C19enzyme
DB01151DesipramineCytochrome P450 2E1enzyme
DB01151DesipramineSphingomyelin phosphodiesterasetarget
DB01151Desipramine5-hydroxytryptamine receptor 1Atarget
DB01151Desipramine5-hydroxytryptamine receptor 2Ctarget
DB01151DesipramineD(2) dopamine receptortarget
DB01151DesipramineAlpha-2 adrenergic receptorstarget
DB00472FluoxetineSodium-dependent serotonin transportertarget
DB00472FluoxetineCytochrome P450 2C9enzyme
DB00472FluoxetineCytochrome P450 2D6enzyme
DB00472FluoxetineCYP2B proteinenzyme
DB00472FluoxetineCytochrome P450 1A2enzyme
DB00472FluoxetineCytochrome P450 3A4enzyme
DB00472FluoxetineCytochrome P450 2C19enzyme
DB00472FluoxetineMultidrug resistance protein 1transporter
DB00472FluoxetineCytochrome P450 2B6enzyme
DB00472FluoxetineCytochrome P450 3A5enzyme
DB00472FluoxetineSerum albumincarrier
DB00472FluoxetineAlpha-1-acid glycoprotein 1carrier
DB00472FluoxetinePotassium voltage-gated channel subfamily H member 2target
DB00472Fluoxetine5-hydroxytryptamine receptor 2Ctarget
DB00472FluoxetineCyclin-dependent kinases regulatory subunit 1target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-2target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-3target
DB00472FluoxetineNeuronal acetylcholine receptor subunit beta-4target
DB00370Mirtazapine5-hydroxytryptamine receptor 2Atarget
DB00370Mirtazapine5HT3 serotonin receptortarget
DB00370MirtazapineAlpha-2A adrenergic receptortarget
DB00370Mirtazapine5-hydroxytryptamine receptor 2Ctarget
DB00370MirtazapineKappa-type opioid receptortarget
DB00370MirtazapineHistamine H1 receptortarget
DB00370MirtazapineCytochrome P450 1A2enzyme
DB00370MirtazapineCytochrome P450 3A4enzyme
DB00370MirtazapineCytochrome P450 2D6enzyme
DB00370MirtazapineAlpha-1 adrenergic receptorstarget
DB00370MirtazapineSodium-dependent serotonin transportertransporter
DrugDrug NamePhaseStatusCount
DB06643Denosumab0Recruiting1
DB00107Oxytocin0Recruiting1
DB00783Estradiol1Withdrawn1
DB01277Mecasermin1 / 2Completed1
DB09123Dienogest2Terminated1
DB00783Estradiol2Completed1
DB00783Estradiol2Not Yet Recruiting1
DB00977Ethinylestradiol2Terminated1
DB13961Fish oil2Completed1
DB00367Levonorgestrel2Completed1
DB00334Olanzapine2Completed1
DB00396Progesterone2Not Yet Recruiting1
DB01224Quetiapine2Terminated1
DB00052Somatotropin2Completed1
DB06285Teriparatide2Active Not Recruiting1
DB00624Testosterone2Completed1
DB00286Conjugated estrogens2 / 3Completed1
DB00783Estradiol2 / 3Completed1
DB01708Prasterone2 / 3Completed1
DB00884Risedronic acid2 / 3Completed1
DB00624Testosterone2 / 3Completed1
DB01238Aripiprazole3Unknown Status1
DB00470Dronabinol3Completed1
DB00783Estradiol3Recruiting1
DB01277Mecasermin3Recruiting1
DB01708Prasterone3Completed1
DB00472Fluoxetine4Completed1
DB00334Olanzapine4Completed1
DB00734Risperidone4Completed1
DB01238AripiprazoleNot AvailableCompleted1
DB00289AtomoxetineNot AvailableCompleted1
DB01511DelorazepamNot AvailableCompleted1
DB00476DuloxetineNot AvailableCompleted1
DB00472FluoxetineNot AvailableCompleted1
DB01064IsoprenalineNot AvailableRecruiting2
DB01277MecaserminNot AvailableActive Not Recruiting1
DB00334OlanzapineNot AvailableCompleted3
DB01224QuetiapineNot AvailableUnknown Status1
DB00884Risedronic acidNot AvailableActive Not Recruiting1
DB09153Sodium chlorideNot AvailableRecruiting1